AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00481078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00481078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00481078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00481078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00481078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02369432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy
Study NCT03204019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur and Temozolomide
Description: Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
Study NCT03204019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur and Temozolomide combined with Thalidomide
Description: Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
Study NCT00044668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
Study NCT03743792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active breakfast
Description: freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
Study NCT03743792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control breakfast
Description: Control drink + buttermilk biscuit sandwich
Study NCT04426279 — intervention group
Intervention type: OTHER
Intervention: questionnaire assesment
Description: 15-minute face-to-face questionnaire
Study NCT01066689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MabThera
Description: MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
Study NCT01066689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum (Sodium Chloride, sodium citrate)
Description: Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
Study NCT01944592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gynaecology Teaching Associates (GTA's)
Description: Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
Study NCT03479489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human dehydrated amnion chorion allograft
Description: Closed hemorrhoidectomy patched with dehydrated human amnion chorion allograft
Study NCT02522039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: 1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
Study NCT02522039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: 1 drop of timolol was given to study eye after washout period of 1 week between drugs
Study NCT01944592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manikin (conventional) training
Description: Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
Study NCT00168324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 µg Dexamethasone
Description: 350 µg Dexamethasone intravitreal implant administered on Day 0.
Study NCT00168324 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham injection on Day 0.
Study NCT02714504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole or posaconazole
Description: Azole with activity against molds
Study NCT03222752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial Electrotherapy Stimulation
Description: Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
Study NCT04198233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazepam 10 mg compounded suppository
Study NCT04198233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo suppository
Study NCT03393468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine gel
Description: Dapivirine gel (0.05%); administered rectally
Study NCT02667548 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention
Study NCT03241238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eating
Description: Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
Study NCT03607474 — intervention group
Intervention type: OTHER
Intervention: Questionnaires of life quality for patients
Description: * the WhoQoL~* a specific scale of Cushing's syndrome~* The Beck II scale~* HAD scale~* Rosenberg questionnaire~* Stunkard, Sorensen and Schlusinger (1983) figurines~* Brief Cope scale
Study NCT03607474 — intervention group
Intervention type: OTHER
Intervention: Questionnaires of life quality for caregivers
Description: * the WhoQoL~* The Beck II scale~* HAD scale
Study NCT02700139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspheric lens
Description: By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
Study NCT01286116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parachute Implant
Description: Mechanical ventricular partitioning
Study NCT03842956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe
Description: We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
Study NCT01975246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan + amlodipine
Description: FDC tablet
Study NCT01975246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: tablet
Study NCT01975246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan + amlodipine
Description: FDC tablet
Study NCT01975246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo matching hydrochlorothiazide tablet
Study NCT03476382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Bone Growth Stimulator
Description: Active device emits ultrasound signals.
Study NCT03222752 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cranial Electrotherapy Stimulation
Description: The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
Study NCT04006912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and Toric intraocular lens implantation
Description: A clear corneal incision is made in a different position
Study NCT04006912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification and Toric intraocular lens implantation
Description: A clear corneal incision is made in a different position
Study NCT03114878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRT / EMDR
Description: Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere.
Study NCT03114878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRT / CBT
Description: Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions.
Study NCT02289859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with Undermining
Description: The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
Study NCT01924962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: revascularisation
Description: revascularisation of chronic occluded coronary artery
Study NCT02289859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure without Undermining
Description: One side of the wound will remain un-undermined.
Study NCT03564041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sahaj Samadhi Meditation (SSM)
Description: This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
Study NCT03564041 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Enhancement Program (HEP)
Description: This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
Study NCT03401450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACB within true AC with bupivacaine 0.5% 20cc
Description: The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.
Study NCT03401450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACB proximal to true AC with bupivacaine 0.5% 20cc
Description: Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
Study NCT02919735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG 428 cutaneous solution
Description: The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
Study NCT02919735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cutaneous solution
Description: The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
Study NCT04008901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BST-104 (Lonicera Flos Extract)
Description: 175 mg of Lonicera Flos extract in 1 tablet (300 mg)
Study NCT04008901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 0 mg of Lonicera Flos extract in 1 tablet (300 mg)
Study NCT04243252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Pantry Program
Description: Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
Study NCT03361384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Study NCT03361384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (non-alcoholic beverage)
Study NCT01507155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genecept Assay
Description: Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
Study NCT02522039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Description: 1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
Study NCT00587041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxadrop
Description: Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
Study NCT00587041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Agri-King Synbiotic (AKSB)
Description: AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
Study NCT00587041 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo packet daily and 1 placebo capsule twice daily
Study NCT02565992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAVATAK
Description: Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
Study NCT02565992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous pembrolizumab at 2 mg/kg solution.
Study NCT02347085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Study NCT02347085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Study NCT03111212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iloprost
Description: Iloprost nebulized
Study NCT03111212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: sodium chloride 0,9% nebulized
Study NCT02739958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol group
Description: Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
Study NCT02739958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoflurane group
Description: Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
Study NCT03475602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PLA2R
Description: Determination of serum concentration of anti PLA2R antibody
Study NCT03475602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TSHD7A
Description: Determination of serum concentration of anti TSHD7A antibody
Study NCT02077231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: use one drop in the eye
Study NCT02077231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbomer eye gel
Description: use one drop in the eye
Study NCT04127526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connection to Environment with Cognitive Therapy (CONNECT)
Description: 8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
Study NCT04243252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
Study NCT05307445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with Bioptron Hyperlight Therapy
Description: The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
Study NCT01819272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets
Study NCT05307445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation with Bioptron Hyperlight Therapy
Description: The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
Study NCT01081821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose NJ-39758979/ matching placebo
Description: Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
Study NCT01081821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multi-dose JNJ-39758979 /matching placebo
Description: JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
Study NCT01969669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
Study NCT01969669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
Study NCT03419221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions
Description: Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community).
Study NCT03419221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
Description: Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
Study NCT01862900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469
Description: Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
Study NCT01819272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met XR
Description: metformin extended-release tablets
Study NCT01819272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo delayed-release tablets
Study NCT03521700 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.